Loading
A phase 1/2 trial of JS105, Fulvestrant, Dalpiciclib, Toripalimab, Pyrotinib and Capecitabine in advanced solid tumours, run by Risen (Suzhou) Pharma Tech Co., Ltd., now recruiting.
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT06208410 by Risen (Suzhou) Pharma Tech Co., Ltd., with 306 participants planned, started 2024-01-11 and due to reach its primary completion in 2027-02-26. Interventions recorded: JS105, Fulvestrant injection, Dalpiciclib Isetionate Tablets, Toripalimab Injection, Paclitaxel for Injection (Albumin Bound) and Fluzoparib Capsules.
Shares Pyrotinib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Dalpiciclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pyrotinib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Toripalimab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.